Privia Health Group (NASDAQ:PRVA) CFO David Mountcastle Sells 7,179 Shares

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 7,179 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $25.03, for a total value of $179,690.37. Following the completion of the sale, the chief financial officer directly owned 214,847 shares of the company’s stock, valued at approximately $5,377,620.41. This trade represents a 3.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Mountcastle also recently made the following trade(s):

• On Monday, May 4th, David Mountcastle sold 1,206 shares of Privia Health Group stock. The stock was sold at an average price of $25.00, for a total value of $30,150.00.
• On Thursday, April 2nd, David Mountcastle sold 5,566 shares of Privia Health Group stock. The stock was sold at an average price of $20.85, for a total value of $116,051.10.
• On Monday, March 16th, David Mountcastle sold 6,391 shares of Privia Health Group stock. The shares were sold at an average price of $22.11, for a total value of $141,305.01.
• On Friday, March 13th, David Mountcastle sold 6,565 shares of Privia Health Group stock. The shares were sold at an average price of $21.52, for a total value of $141,278.80.
• On Thursday, March 12th, David Mountcastle sold 6,453 shares of Privia Health Group stock. The shares were sold at an average price of $21.90, for a total value of $141,320.70.
• On Monday, March 9th, David Mountcastle sold 5,829 shares of Privia Health Group stock. The shares were sold at an average price of $22.84, for a total value of $133,134.36.
• On Friday, March 6th, David Mountcastle sold 5,177 shares of Privia Health Group stock. The shares were sold at an average price of $23.15, for a total value of $119,847.55.
• On Thursday, February 26th, David Mountcastle sold 5,361 shares of Privia Health Group stock. The shares were sold at an average price of $25.00, for a total value of $134,025.00.
• On Friday, February 27th, David Mountcastle sold 7,697 shares of Privia Health Group stock. The shares were sold at an average price of $25.05, for a total value of $192,809.85.

Privia Health Group Trading Up 0.2%

PRVA opened at $24.29 on Wednesday. The stock has a market cap of $3.05 billion, a price-to-earnings ratio of 142.88, a PEG ratio of 1.51 and a beta of 0.96. Privia Health Group, Inc. has a 1 year low of $18.77 and a 1 year high of $26.51. The stock has a fifty day moving average price of $22.64 and a 200 day moving average price of $23.36.

Privia Health Group (NASDAQ:PRVA) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.21. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The firm had revenue of $541.17 million during the quarter, compared to analysts’ expectations of $516.61 million. During the same quarter last year, the firm earned $0.21 earnings per share. The business’s revenue for the quarter was up 17.4% on a year-over-year basis. As a group, sell-side analysts forecast that Privia Health Group, Inc. will post 0.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Privia Health Group

A number of institutional investors have recently made changes to their positions in PRVA. Bayban bought a new position in shares of Privia Health Group in the fourth quarter worth about $26,000. Hantz Financial Services Inc. increased its stake in Privia Health Group by 456.2% during the fourth quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock valued at $27,000 after acquiring an additional 926 shares during the period. Global Retirement Partners LLC increased its stake in Privia Health Group by 579.8% during the fourth quarter. Global Retirement Partners LLC now owns 1,584 shares of the company’s stock valued at $38,000 after acquiring an additional 1,351 shares during the period. Canada Pension Plan Investment Board increased its stake in Privia Health Group by 48.0% during the second quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock valued at $85,000 after acquiring an additional 1,200 shares during the period. Finally, Kestra Advisory Services LLC bought a new position in Privia Health Group during the fourth quarter valued at about $93,000. 94.48% of the stock is currently owned by institutional investors.

Privia Health Group News Summary

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Recent operating momentum — Privia beat consensus in its prior quarter (reported 2/26: $0.25 EPS vs. $0.04 est; revenue $541.2M vs. $516.6M; revenue +17.4% YoY), which supports the view that the company can continue to grow revenue and expand services. MarketBeat PRVA profile
• Neutral Sentiment: Q1 earnings event — Privia is scheduled to report Q1 results on Thursday; previews point to investor focus on revenue growth, margin trends and FY guidance. The upcoming release is the main near-term catalyst. Privia to Release Earnings
• Neutral Sentiment: Analyst/preview coverage — Recent previews summarize expectations and items to watch heading into the print (revenue, patient volumes, cost structure). These previews set a framework for whether the stock reaction will be driven by beats, guidance, or execution detail. MSN Q1 preview
• Negative Sentiment: Insider selling — CFO David Mountcastle disclosed Rule 10b5-1 sales (7,179 shares on May 1 at ~$25.03 and 1,206 shares on May 4 at ~$25.00). While pre-arranged plans reduce governance concerns, these transactions can pressure sentiment in the short term. CFO Form 4
• Negative Sentiment: Director selling — Director Matthew Shawn Morris sold 17,096 shares (May 1, ~$24.99) and 1,017 shares (May 4, ~$24.96) under a 10b5-1 plan, a meaningful reduction in his holding. Again, the 10b5-1 context tempers governance concerns but may weigh on near-term sentiment. Director Form 4

Analyst Ratings Changes

A number of analysts have weighed in on PRVA shares. Citigroup reduced their price target on Privia Health Group from $34.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, March 3rd. Canaccord Genuity Group boosted their price target on Privia Health Group from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $32.00 price target on shares of Privia Health Group in a research report on Thursday, February 26th. Piper Sandler reiterated an “overweight” rating and issued a $36.00 price objective on shares of Privia Health Group in a research note on Thursday, February 26th. Finally, Evercore set a $26.00 price objective on Privia Health Group in a research note on Wednesday, April 8th. Eleven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.31.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.